Partner Headlines - INFI

  1. JPM Securities Picks Through Biotech News For Winners

    Benzinga
  2. UPDATE: Infinity Pharmaceuticals Posts Q4 Loss

    Benzinga
  3. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  4. Morning Market Losers

    Benzinga
  5. Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday ...

    Benzinga
  6. Benzinga's Top #PreMarket Losers

    Benzinga
  7. Infinity Announces Clinical And Preclincal Data For Duvelisib ...

    Benzinga
  8. Infinity Reports Topline Data From Phase 2a Exploratory Study ...

    Benzinga
  9. 3 Partnerships Pushing The Pharmaceutical Sector Forward

    Benzinga
  10. Pharmacyclics Price Target Cut On Higher Spending

    IBD
  11. Benzinga's Top Upgrades

    Benzinga
  12. JMP Securities Upgrades Infinity Pharmaceuticals To Market Outperform

    Benzinga
  13. Infinity, AbbVie team on drug

    IBD
  14. S&P 500 Struggles To Hold 2,000 As Commodities Rebound

    Benzinga
  15. Midday Gainers From Wednesday, September 3

    Benzinga
  16. Infinity Pharma Joins AbbVie On Blood Cancer Drug

    IBD
  17. NASDAQ Tumbles 0.5%; Infinity Pharmaceuticals Jumps On Deal With ...

    Benzinga
  18. Markets Gain; Toll Brothers Profit Beats Estimates

    Benzinga
  19. Benzinga's Volume Movers

    Benzinga
  20. Morning Market Movers

    Benzinga
  21. Stock Futures Up And Climbing; Baidu Heads China Stock Rally

    IBD
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. What You Need to Know About the Roche-InterMune Deal

    Benzinga
  24. Markets Open Higher; Burger King In Talks To Buy Tim Hortons

    Benzinga
  25. InterMune's Roche Deal Sends Peer Group Up

    Benzinga
  26. 3 Small-Cap Biotechs That Institutions Are Loving

    Benzinga
  27. UPDATE: Morgan Stanley Initiates Coverage On Infinity Pharmaceuticals ...

    Benzinga
  28. The Top Five Drug Launches Of 2013

    IBD
  29. UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on ...

    Benzinga
  30. Benzinga's Top Downgrades

    Benzinga
  31. Celgene's stock hits new high

    IBD
  32. Mid-Day Market Update: Sysco Shares Rise Following Merger with ...

    Benzinga
  33. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD
  34. Benzinga's Volume Movers

    Benzinga
  35. Infinity Reports Encouraging Phase 1 IPI-145 Data at ASH

    Benzinga
  36. Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ...

    Benzinga
  37. Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ...

    Benzinga
  38. UPDATE: William Blair Initiates Coverage on Infinity Pharmaceuticals ...

    Benzinga
  39. Benzinga's Top Initiations

    Benzinga
  40. The Best Small Cap Performers of 2012

    Benzinga
  41. Stocks Hitting 52-Week Highs

    Benzinga
  42. Infinity Pharma Amends Millennium Deal for PI3K-Delta, Gamma

    Benzinga
  43. Infinity Announces Amended PI3K-Delta,Gamma Agreement with Millennium

    Benzinga
  44. Infinity Announces Closing of Public Offering and Exercise of ...

    Benzinga
  45. Stocks Hitting 52-Week Highs

    Benzinga
  46. Infinity Pharma Prices 5.696M Shares at $26.33

    Benzinga
  47. Mid-Afternoon Market Update: Markets Continue to Rise, Diamond ...

    Benzinga
  48. Infinity Pharma Shares Rebound Over $22 Following Phase I Data ...

    Benzinga
  49. UPDATE: Jefferies Downgrades Infinity Pharmaceuticals to Hold ...

    Benzinga
  50. INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q)

    GuruFocus
  51. Stocks Hitting 52-Week Highs

    Benzinga
  52. UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at ...

    Benzinga
  53. INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q)

    GuruFocus
  54. Health Care Sector Wrap

    FoxBusiness
  55. Synacor, American Capital Mortgage Investment Crp, Other Stocks ...

    FoxBusiness
  56. Infinity Pharmaceuticals Shuts Down Cancer Trials

    Benzinga
  57. Morning Market Losers

    Benzinga
  58. Benzinga's Top Pre-Market Losers

    Benzinga
  59. A Peek Into The Market Before The Trading Starts

    Benzinga
  60. UPDATE: Piper Jaffray Lowers PT on Infinity Pharmaceuticals to ...

    Benzinga
  61. Infinity Plummets on Disappointing Phase 2 Study

    Benzinga
  62. Piper Jaffray Lowers PT on Infinity Pharmaceuticals to $8

    Benzinga
  63. Infinity Reports Update from Phase 2 Study of Saridegib Plus ...

    Benzinga
  64. Infinity Reports New Data from Phase 1b Trial of Saridegib in ...

    Benzinga
Trading Center